Vetigenics

www.vetigenics.com

At Vetigenics, we harness the power of the animal's own immune system to bring the latest advancements in biotechnology to improve pet health. Vetigenics, founded by Nicola Mason BVetMD, PhD and Don Siegel PhD, MD both Professors at UPenn, have created the only comprehensive, canine single chain fragment variable (scFv) phage display libraries estimated to contain over 40 billion independent scFv members. CANIBODIES™ are entirely canine scFvs uniquely selected from the library based on their antigen-binding capabilities, functionality and developability. As they are generated from native canine immunoglobulin germline genes, they do not require caninization or chimeric (mouse/canine) design and offer reduced immunogenicity when compared to antibodies generated by competitive methods. Furthermore, as the library’s repertoire is not limited by central tolerance, CANIBODIES™ are highly versatile, can be rapidly, readily isolated and engineered into alternative therapeutic formats such as full-length canine IgGs, BiTEs, and CAR-T cell constructs. Working closely with a wide network of experts in animal and human health, Vetigenics is devoted advancing our portfolio of drug candidates to enhance and extend the lives of our cherished companions. For more information contact: Adriann Sax, CEO asax@vetigenics.com

Read more

Reach decision makers at Vetigenics

Lusha Magic

Free credit every month!

At Vetigenics, we harness the power of the animal's own immune system to bring the latest advancements in biotechnology to improve pet health. Vetigenics, founded by Nicola Mason BVetMD, PhD and Don Siegel PhD, MD both Professors at UPenn, have created the only comprehensive, canine single chain fragment variable (scFv) phage display libraries estimated to contain over 40 billion independent scFv members. CANIBODIES™ are entirely canine scFvs uniquely selected from the library based on their antigen-binding capabilities, functionality and developability. As they are generated from native canine immunoglobulin germline genes, they do not require caninization or chimeric (mouse/canine) design and offer reduced immunogenicity when compared to antibodies generated by competitive methods. Furthermore, as the library’s repertoire is not limited by central tolerance, CANIBODIES™ are highly versatile, can be rapidly, readily isolated and engineered into alternative therapeutic formats such as full-length canine IgGs, BiTEs, and CAR-T cell constructs. Working closely with a wide network of experts in animal and human health, Vetigenics is devoted advancing our portfolio of drug candidates to enhance and extend the lives of our cherished companions. For more information contact: Adriann Sax, CEO asax@vetigenics.com

Read more
icon

Country

icon

State

Pennsylvania

icon

City (Headquarters)

Philadelphia

icon

Employees

1-10

icon

Founded

2017

icon

Social

  • icon
  • icon

Employees statistics

View all employees

Potential Decision Makers

  • President , Chief Executive Officer and Co Founder

    Email ****** @****.com
    Phone (***) ****-****

Technologies

(10)

Reach decision makers at Vetigenics

Free credits every month!

My account

Sign up now to uncover all the contact details